Patents Assigned to Heart Research Institute, Ltd.
-
Publication number: 20230416341Abstract: The invention relates to the treatment of thromboembolic conditions, to fibrin clot formation and related thrombin activity, and to preparation of compounds, in particular, peptides and polypeptides for inhibiting, or for modifying the cleavage of fibrinogen by thrombin.Type: ApplicationFiled: June 19, 2020Publication date: December 28, 2023Applicants: THE UNIVERSITY OF SYDNEY, THE HEART RESEARCH INSTITUTE LTDInventors: Richard J PAYNE, Emma WATSON, Shaun Phillip JACKSON
-
Patent number: 10300175Abstract: A plasma-activated coating (PAC) process covalently binds enzymes in their bioactive state, has low thrombogenicity and can be robustly applied to medical devices, resisting delamination when deployed in vivo. Applying this process to attachment of proteins such as enzymes that inhibit thrombosis and anticoagulants such as heparin or heparin fragments, one can produce medical devices and other materials for use in vascular applications having a number of benefits including covalent attachment, not requiring intermediate linkers or chemistry; substrate independent—works on polymers, metals, ceramics, 3D shapes like stents, valves, etc.; bioactivity is retained; surface may retain greater bioactivity over time in vivo; Simultaneously supports endothelialization; can be stored for long periods, following freeze drying, and retains effectiveness when rehydrated and; surface is able to bind many fibrinolytic enzymes such as streptokinase, urokinase, tPA, plasmin).Type: GrantFiled: September 11, 2015Date of Patent: May 28, 2019Assignee: Heart Research Institute, Ltd.Inventors: Steven G. Wise, Martin K. C. Ng
-
Patent number: 9572817Abstract: The present invention relates to the field of therapy and prophylaxis of vascular tissue damage and/or complications and/or disease of vascular tissue by vascular regeneration and endothelium repair. The inventors have found that administration of an androgen receptor agonist alleviates one or more adverse vascular diseases and/or vascular complications thereof or adverse effects of androgen deficiency, with implications for prophylactic and therapeutic interventions.Type: GrantFiled: July 4, 2008Date of Patent: February 21, 2017Assignee: THE HEART RESEARCH INSTITUTE LTD.Inventors: Daniel Peter Sieveking, Martin Kean Chong Ng
-
Publication number: 20150191446Abstract: Compounds and compositions, useful as antioxidants and in particular to selenium containing compounds of formula (I): wherein n is 1, 2, or 3; m is 2, 3, 4, or 5; and each R] is independently-(optionally substituted C1-C3 alkylene)p-OH, where p is 0 or 1, or a salt thereof. These seleno-compounds may be used in the treatment of diseases or conditions associated with increased levels of oxidants produced by myeloperoxidase (MPA), such as for instance, atherosclerosis and diabetes.Type: ApplicationFiled: October 10, 2014Publication date: July 9, 2015Applicants: THE HEART RESEARCH INSTITUTE LTD, THE UNIVERSITY OF MELBOURNEInventors: Carl Herbert SCHIESSER, Corin STORKEY, Michael Jonathan DAVIES
-
Publication number: 20140206658Abstract: The present invention relates to compounds and compositions useful as antioxidants and in particular to selenium containing compounds of formula (I): wherein n is 1, 2, or 3; m is 2, 3, 4, or 5; and each R] is independently —(optionally substituted C1-C3 alkylene) p-OH, where p is 0 or 1, or a salt thereof. The invention also relates to the use of these seleno-compounds in the treatment of diseases or conditions associated with increased levels of oxidants produced by myeloperoxidase (MPO), such as for instance, atherosclerosis.Type: ApplicationFiled: October 28, 2011Publication date: July 24, 2014Applicants: THE HEART RESEARCH INSTITUTE LTD., THE UNIVERSITY OF MELBOURNEInventors: Carl Herbert Schiesser, Corin Storkey, Michael Jonathan Davies
-
Publication number: 20060177888Abstract: Herein provided is a method for evaluating the antioxidant potential of a biological sample comprising the steps of: (a) collecting a sample containing at least oxidizable substrates from a living body; (b) initiating an oxidation reaction of said oxidizable substrates; (c) continuing said oxidation reaction; and (d) quantifying oxidation products formed from said oxidizable substrates by determining the rate of said oxidation reaction during the progress thereof or by performing an assay after said oxidation reaction has been stopped, wherein said steps (b) and (c) are performed in the presence of one or more antioxidant components.Type: ApplicationFiled: March 22, 2004Publication date: August 10, 2006Applicants: Chugai Seiyaku Kabushiki Kaisha, The Heart Research Institute Ltd.Inventors: Osamu Cynshi, Roland Stocker
-
Patent number: 6989397Abstract: The present invention provides 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) analogues suitable for use as an in vivo iron chelators, the PCIH analogue having Formula 1: wherein R1 is an aromatic or heterocyclic group and R2 is either H or OH; isomers thereof or salts thereof; pharmaceutical compositions containing the analogues; and uses of the analogues in the treatment of iron-overload diseases.Type: GrantFiled: September 4, 2000Date of Patent: January 24, 2006Assignees: University of Queensland, The Heart Research Institute Ltd.Inventors: Des Richardson, Paul Vincent Bernhardt, Erika Michelle Becker
-
Patent number: 6031008Abstract: Disclosed is a method for screening and/or testing in vitro of synthetic or natural compounds for antioxidant potency. Further disclosed is the use of 3,3',5,5'-tetra-tert-butyl-4,4'-bisphenol and pharmaceutical preparations thereof in restoring endothelial function.Type: GrantFiled: August 22, 1997Date of Patent: February 29, 2000Assignee: The Heart Research Institute Ltd.Inventors: Ann-Margret Lindqvist, Knut Pettersson, Roland Stocker, Christer Westerlund, Paul Witting
-
Patent number: 5731166Abstract: The chemotactic protein CP-10, in essentially pure form, having an apparent molecular weight of approximately 10 kD and having chemotactic activity for neutrophils, monocytes/macrophages and/or other mammalian cells, or an analogue, mutant, fragment, derivative or functional homologue of CP-10. Amino acid and nucleotide sequences for CP-10 are disclosed, as well as production and use thereof.Type: GrantFiled: April 23, 1993Date of Patent: March 24, 1998Assignee: The Heart Research Institute Ltd.Inventors: Carolyn Geczy, Richard John Simpson, Martin Lackmann